Organization, Description of the Business and Liquidity (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Feb. 17, 2017	Dec. 31, 2016
Schedule of Equity Method Investments [Line Items]
Accumulated deficit	$ (71,319)	$ (54,677)
Cash and cash equivalents	8,034	$ 7,600		$ 10,174
BioTime and AgeX Therapeutics shares held as marketable equity securities, at fair value	400
February 2019 [Member]
Schedule of Equity Method Investments [Line Items]
Proceeds from public offering	$ 37,400
Sale of common stock shares	10,733,334
BioTime, Inc. [Member]
Schedule of Equity Method Investments [Line Items]
Equity ownership percentage			50.00%	51.10%
BioTime and AgeX Therapeutics shares held as marketable equity securities, at fair value	$ 428
Sale of common stock shares		266,442